|
|
|
|
|
 |
||||||||
|
|||||||||
 |
|
|
|
|
|
|
|
|
Management Board of Directors Advisory Board Investors |
|
|
|
Home > Our Team > Board of Directors BOARD OF DIRECTORS Ed Brennan, PhD - President and CEO David Cooney - Beecken Petty & Company Jerry C. Griffin, MD, FACC - Director J. Mark Hattendorf - Director Arda M. Minocherhomjee, Ph.D. - Managing Director, Chicago Growth Partners Kurt Wheeler - General Partner, MPM Capital LP Ed Brennan, PhD President and CEO Edward F. Brennan, Ph.D., has served as our Chief Operating Officer since January 2005, our President since March 2005 and our Chief Executive Officer and a member of our board of directors since March 2006. From January 2001 to December 2003, Dr. Brennan was Managing Director for Perennial Ventures, a venture fund focused on early-stage investing in technology companies. From January 2000 to December 2000, Dr. Brennan served as Vice President of Tredegar Investments, a venture capital investment company. Dr. Brennan was also Executive Vice President for CardioGenesis Corp., a medical device company, from June 1995 to December 1999, where he was responsible for domestic and international clinical programs, regulatory affairs, quality systems and scientific research activities. He is the Chairman of Hemosense, Inc., and serves on the boards of directors of a number of privately-held technology companies. Dr. Brennan received a B.A. in Chemistry and Biology and a Ph.D. in Biology from the University of California, Santa Cruz. [ back to top ]
David Cooney [ back to top ]
Jerry C. Griffin, MD, FACC Director Dr. Griffin has over nine years experience working in the biotech and medical technologies industry and 23 years in clinical research and academic teaching focused on cardiology disease, most recently as CEO of Point Biomedical. Prior to Point Biomedical, Dr. Griffin worked from 1992 to 1998 at InControl, Inc. serving last as Executive Vice President responsible for worldwide regulatory affairs and clinical development activities and prior to that served as Vice President Medical Affairs. Dr. Griffin also has worked actively in strategic consulting assignments for various development stage medical technology companies including HeartStent, Inc., Transneuronix, Inc., InFlow Dynamics, Inc., Atrionix, Inc. and PharmaSonics, Inc. Prior to his recent industry experience, Dr. Griffin served as a full time faculty member in the Department of Medicine, Division of Cardiology at several renowned teaching institutions including Professor of Medicine at the University of California at San Francisco; Assistant Professor at Baylor College of Medicine; and Clinical Assistant Professor of Medicine at Stanford University. Dr. Griffin earned a B.S. degree at the University of Southern Mississippi, a M.D. degree at the University of Mississippi, and earned a Fellow in Cardiology at Stanford University. [ back to top ]
J. Mark Hattendorf Director Mr. Hattendorf has over 30 years of experience in accounting, finance and business management, including as the senior financial officer for a number of publicly and privately-held companies. He has experience serving on the board of directors of publicly-held and not-for-profit entities. He is a Certified Public Accountant and holds an undergraduate degree in Accounting and an MBA in Finance from Loyola Marymount University in Los Angeles, California. [ back to top ]
Arda M. Minocherhomjee, Ph.D. [ back to top ]
Kurt Wheeler General Partner, MPM Capital LP Prior to joining MPM in 1999, Mr. Wheeler was Chairman and CEO of InControl, Inc., a publicly traded medical device company that designed, developed, and marketed implantable medical devices to treat irregular heart rhythms. In September 1998, Mr. Wheeler negotiated the sale of InControl to Guidant Corporation. He serves on the Board of Directors of CryoCor, IntraTherapeutics, Intellicardia, Intraluminal Therapeutics, Scout Medical, Vidamed, Xoft MicroTube, and Optiscan Biomedical, where he is Chairman. Previously, he was on the Board of Heartstream, which was acquired by Hewlett Packard. Prior to InControl, Mr. Wheeler was a principal in the life science group at the Mayfield Fund, a venture capital partnership. He has participated in the early stage development of several biotechnology companies including Sungene Technologies, Affymax NV, and Cell Genesys. He began his professional career at Eli Lilly & Co. He holds a B.A. degree from Brigham Young University and a M.B.A. degree from Northwestern University, where he serves on the Kellogg Alumni Advisory Board. [ back to top ]
|
|
|
|
Home | Corporate Profile | Products | Clinical Trials | Our Team | Investors | Careers | Contact Privacy Policy | Site Map © 2005 CryoCor, Inc. |
